The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry

Current Medicinal Chemistry

Volumn 16, Issue 14, 2009, Pages 1746-1767

  Mugnaini, Claudia ^a   Pasquini, Serena ^a   Corelli, Federico ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Anti tumor agents; CB2 agonists; Drug design; HIV 1 integrase inhibitors; Privileged structure; Quinolones

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 1,8 NAPHTHYRIDIN 4(1H) ON 3 CARBOXAMIDE DERIVATIVE; 3 ETHOXYCARBONYL 4 QUINOLONE DERIVATIVE; 4 CYANOPHENYL DERIVATIVE; 4 QUINOLONE 3 CARBOXYLIC ACID DERIVATIVE; 4 QUINOLONE DERIVATIVE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 AMINOQUINOLONE DERIVATIVE; 6 DESFLUOQUINOLONE DERIVATIVE; 6 FLUOQUINOLONE DERIVATIVE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACICLOVIR; ANTIVIRUS AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CARBOXYLIC ACID; CIPROFLOXACIN; ELVITEGRAVIR; FLUORINATED QUINOLONE DERIVATIVE; FLUOROQUINOLONENUCLEOSIDE DERIVATIVE; PLACEBO; PNU 183792; QUINOLONE ACYCLONUCLEOSIDE DERIVATIVE; RALTEGRAVIR; RIMONABANT; SQ 4004; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INTEGRASE INHIBITOR; QUINOLONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BRAIN ISCHEMIA; CARBONYLATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG DETERMINATION; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN;

ANTINEOPLASTIC AGENTS; CARBOXYLIC ACIDS; DRUG DESIGN; HIV INTEGRASE INHIBITORS; QUINOLONES; RECEPTOR, CANNABINOID, CB2;

EID: 67651047155     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788186156     Document Type: Review

References (98)

1. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfieldt, J. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem., 1988, 31, 2235-2246.
2. DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin; D. A. Privileged structures: Applications in drug discovery. Comb. Chem. High Throughput Screen., 2004, 7, 473-493.
3. Lesher, G. Y.; Froelich, E. J.; Gruett, M. D.; Bailey, J. H., Brungaje, R. P. 1,8-Naphthyridine derivatives: A new class of chemotherapeutic agents. J. Med. Pharm. Chem., 1962, 5, 1063-1068.
4. Ertl, P.; Jelfs, S.; Mühlbacher, J.; Schuffenhauer, A.; Selzer, P. Quest for rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds. J. Med. Chem., 2006, 49, 4568-4573.
5. Letafat, B.; Emami, S.; Mohammadhosseini, N.; Faramarzi, M. A.; Samadi, N.; Shafiee, A.; Foroumadi, A. Synthesis and antibacterial activity of new N-[2-(thiophen-3-yl)ethyl]piperazinyl quinolones. Chem. Pharm. Bull. (Tokyo), 2007, 55, 894-898.
6. Srivastava, B. K, Solanki, M., Mishra, B., Soni, R., Jayadev, S., Valani, D., Jain, M., Patel, P.R. Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. Bioorg. Med. Chem. Lett., 2007, 17, 1924-1929.
7. Wang, Q.; Lucien, E.; Hashimoto, A.; Pais, G. C.; Nelson, D. M.; Song, Y.; Thanassi, J. A.; Marlor, C. W.; Thoma, C. L.; Cheng, J.; Podos, S. D.; Ou, Y.; Deshpande, M.; Pucci, M. J.; Buechter, D. D.; Bradbury, B. J.; Wiles, J. A. Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: Effects of structural modifications at the 6-, 7-, and 8- positions. J. Med. Chem., 2007, 50, 199-210.
8. Hirata, T.; Onodera, Y.; Hoshino, K.; Otani, T.; Yamamoto, T. Dual-targeting properties of the 3-aminopyrrolidinyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: Contribution to reducing in vitro emergence of quinoloneresistant Streptococcus pneumoniae. J. Antimicrob. Chemother., 2008, 62, 98-104.
9. Tsukamura, M. In vitro antituberculosis activity of a new antibacterial substance, ofloxacin (DL8280). Am. Rev. Resp. Dis., 1985, 131, 348-351.
10. O'Brien, R. J. Development of fluoroquinolones as first-line drugs for tuberculosis at long last! Am. J. Respir. Crit. Care Med., 2003, 168, 1266-1268.
11. Janin, Y. L. Antituberculosis drugs: Ten years of research. Bioorg. Med. Chem., 2007, 15, 2479-2513.
12. Mdluli, K.; Ma, Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect. Disord. Drug Targets, 2007, 7, 159-168.
13. Gould, R. Jr.; Jacobs, W.A. The synthesis of certain substituted quinolones and 5,6-benzoquinolines. J. Am. Chem. Soc., 1939, 61, 2890-2895.
14. Lappin, G. Cyclization of 2-aminopyridine derivatives. I. Substituted ethyl 2-pyridylaminomethylene malonate. J. Am. Chem. Soc., 1948, 70, 3348-3350.
15. Grohe, R.; Heitzer, H. Cycloaracylation of enamines. I. Synthesis of 4-quinolone-3-carboxylic acids. Liebigs Ann. Chem., 1987, 1, 29-37.
16. Cecchetti, V.; Fravolini, A.; Lorenzini, M. C.; Tabarrini, C.; Terni, P.; Xin, T. Studies on 6-aminoquinolones: Synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. J. Med. Chem., 1996, 39, 436-445.
17. MacDonald, A. A.; DeWitt, S. H.; Hogan, E. M.; Ramage, R. A solid phase approach to quinolones using the DIVERSOMER® technology. Tetrahedron Lett., 1996, 37, 4815-4818.
18. Obrecht, D.; Villalgordo, J. M. Solid-supported combinatorial and parallel synthesis of small-molecular-weight compound libraries, Elsevier Science: Amsterdam, 1998.
19. Torii, S.; Okumoto, H.; Xu, L. H. A direct approach to 2-substituted 1,4 dihydro-4-oxo-quinoline-3-carboxylates by palladium-catalyzed carbonylative cyclization. Tetrahedron Lett., 1990, 31, 7175-7178.
20. Hooper, D. C. Mode of action of fluoroquinolones. Drugs, 1999, 58 (Suppl. 2), 6-10.
21. Berger, J. M.; Gamblin, S. J.; Harrison, S. C.; Wang, J. C. Structure and mechanism of DNA topoisomerase II. Nature, 1996, 379, 225-232.
22. Burden, D. A.; Osheroff, N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1998, 1400, 139-154.
23. Kohlbrenner, W. E.; Wideburg, N.; Weigl, D.; Saldivar, A.; Chu, D. T. W. Induction of calf thymus topoisomerase II-mediated DNA breakage by antibacterial isothiazoloquinolones A-65281 and A-65282. Antimicrob. Agents Chemother., 1992, 36, 81-86.
24. Robinson, M. J.; Martin, B. A.; Gootz, T. D.; Mcguirk, P. R.; Osheroff, N. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob. Agents Chemother., 1992, 36, 751-756.
25. Permana, P. A.; Snapka, R. M.; Shen, L. L.; Chu, D. T. W.; Clement, J. J.; Plattern, J. J. Quinobenzoxazine: A class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry, 1994, 33, 11333-11339
26. Tomita, K.; Tsuzuki, Y.; Shibamori, K. -I.; Tashima, M.; Kajikawa, F.; Sato, Y.; Kashimoto, S.; Chiba, K.; Hino, K. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 1 J. Med. Chem., 2002, 45, 5564-5575.
27. Tsuzuki, Y.; Tomita, K.; Shibamori, K. -I.; Sato, Y.; Kashimoto, S.; Chiba, K. Synthesis and structure-activity relationship of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J. Med. Chem., 2004, 47, 2097-2109.
28. Bromberg, J.; Darnell, J. E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 2000, 19, 2468-2473.
29. Levy, D. E.; Darnell, J. E. STATs: Transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol., 2002, 3, 651-662.
30. Klampfer, L. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets, 2006, 6, 107-121.
31. Darnell, J. E. Validating STAT3 in cancer therapy. Nat. Med., 2005, 11, 595-596.
32. Jing, N.; Tweardy, D. J. Targeting STAT3 in cancer therapy. Anti-Cancer Drugs 2005, 16, 601-607.
33. Xu, J.; Cole, D. C.; Chang, C.-P. B.; Ayyad, R.; Asselin, M.; Hao, W.; Gibbons, J.; Jelinsky, S. A.; Saraf, K. A.; Park, K. Inhibition of the signal transducer and activator of transcription-3 (STAT3) signaling pathway by 4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxylic acid esters J. Med. Chem., 2008, 51, 4115-4121.
34. Golub, A. G.; Yakovenko, O. Y.; Bdzhola, V. G.; Sapelkin, V. M.; Zien, P.; Yarmoluk, S. M. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J. Med. Chem., 2006, 49, 6443-6450.
35. Rudolph, U.; Crestani, F.; Benke, D.; Brunig, I.; Benson, J. A.; Fritschy, J. M.; Martin, J. R.; Bluethmann, H.; Mohler, H. Benzodiazepine actions mediated by specific gamma-aminobutyrric acid (A) receptor subtypes. Nature, 1999, 401(6755), 796-800.
36. Kahnberg, P.; Howard, M. H.; Liljefors, T.; Nielsen, M.; N., Elsebet O.; Sterner, O.; Pettersson, I. The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABAA receptor. J. Mol. Graph. Model., 2004, 23, 253-261.
37. Lager, E.; Andersson, P.; Nilsson, J.; Pettersson, I.; Nielsen, E. O.; Nielsen, M.; Sterner, O.; Lilijefors, T. 4-Quinolone derivatives: High affinity ligands at the benzodiazepine site of brain GABAA receptors: synthesis, pharmacology and pharmacophore modeling. J. Med. Chem., 2006, 49, 2526-2533.
38. Park, C-H.; Lee, J.; Jung, H. Y.; Kim, M. J.; Lim, S. H.; Yeo, H. T.; Choi, E. C.; Yoon, E. J.; Kim, K. W.; Cha, J. H.; Kim, S. H.; Chang, D. J.; Kwon, D. Y.; Li, F.; Suh, Y. G. Identification, biological activity, and mechanism of the anti-ischemic quinolone analog. Bioorg. Med. Chem., 2007, 15, 6517-6526.
39. [39] Lucero, B. d'A.; Gomes, C. R. B., Frugulhetti, I. C. de P. P., Faro, L. V.; Alvarenga, L.; De Souza, M. C. B. V.; De Souza, T. M. L.; Ferreira, V. F. Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues. Bioorg. Med. Chem. Lett., 2006, 16, 1010-1013.
40. Oien, N.L.; Brideau, R.J.; Hopkins, T.A.; Wieber, J.L.; Knechtel, M.L.; Shelly, J.A.; Anstadt, R.A.; Wells, P.A.; Poorman, R.A.; Huang, A.; Vaillancourt, V.A.; Clayton, T.L.; Tucker, J.A.; Wathen, M.W. Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother, 2002, 46, 724-730.
41. Brideau, R.J.; Knechtel, M.L.; Huang, A.; Vaillancourt, V.A.; Vera, E.E.; Oien, N.L.; Hopkins, T.A.; Wieber, J:L.; Wilkinson, K.F.; Rush, B.D.; Schwende, F.J.; Wathen, M.W. Broad-spectrum antiviral activity of PNU-183792, a 4-oxodihydroquinoline, against human and animal herpesviruses. Antiv. Res., 2002, 54, 19-28.
42. Daelemans, D.; Vandamme, A.M.; De Clercq, E. Human immunodeficiency virus gene regulation as target for antiviral chemotherapy. Antivir. Chem. Chemother., 1999, 10, 1-10.
43. Baba, M.; Okamoto, M.; Makino, M.; Kimura, Y.; Ikeuchi, T.; Sakaguchi, T.; Okamoto, T. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother., 1997, 41, 1250-1255.
44. Witvrouv, M.; Daelemans, D.; Pannecouque, C.; Neyts, J.; Andrel, G.; Snoeck, R.; Vandamme, A.; Balzarini, J.; Desmyter, J.; Baba, M.; De Clercq, E. Broad-spectrum antiviral activity and mechanism of antiviral action of fluoroquinolone derivative K-12. Antiviral Chem. Chemother., 1998, 5, 403-411.
45. Baba, M.; Okamoto, M.; Kawamura, M.; Makino, M.; Higashida, M.; Takashi, T.; Kimura, Y.; Ikeuchi, T.; Tetsuka, T.; Okamoto, T. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol,. 1998, 53, 1097-1103.
46. Parolin, C.; Gatto, B.; Del Vecchio, C.; Pacere, T.; Tramontano, E.; Cecchetti, V.; Fravolini, A.; Masiero, S.; Palumbo, M.; Palù, G. New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. Antimicrob. Agents Chemother. 2003, 47, 889-896.
47. Tabarrini, O.; Stevens, M.; Cecchetti, V.; Sabatini, S.; Dell'Uomo, M.; Manfroni, G.; Palumbo, M.; Pannecouque, C.; De Clercq, E.; Fravolini, A. Structure modifications of 6-aminoquinolones with potent anti-HIV activity. J. Med. Chem., 2004, 47, 5567-5578.
48. Tabarrini, O.; Massari, S.; Daelemans, D.; Stevens, M.; Manfroni, G.; Sabatini, S.; Balzarini, J.; Cecchetti, V.; Pannecouque, C.; Fravolini, A. Structure-activity relationship study on anti-HIV 6-desfluoroquinolones. J. Med. Chem., 2008, 51, 5454-5458.
49. Stevens, M.; Pollicita, M.; Pannecouque, C.; Verbeken, E.; Tabarrini, O.; Cecchetti, V.; Acquaro, S.; Perno, C.F.; Fravolini, A.; Schols, D.; De Clercq, E; Balzarini, J. A novel in vivo model for the study of HIV-1 transcription inhibitors: Evaluation of new 6-desfluoroquinolone derivatives (6-DFQs). Antimicrob. Agents Chemother., 2007, 4, 1407-1413.
50. Bushman, F. D.; Craigie, R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: Specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. U. S. A., 1991, 88, 1339-1343.
51. Brown, P. O. Integration. In Retro Viruses; Coffin, J. M., Hughes, S. H., Varmus, H. E., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1997; pp 161-203.
52. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: A 10-year saga. Expert Opin. Ther. Pat., 2002, 12, 709-724.
53. Dayam, R.; Neamati, N. Small-molecule HIV-1 integrase inhibitors: The 2001-2002 update. Curr. Pharm. Des., 2003, 9, 1789-1802.
54. Pommier, Y.; Johnson, A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov., 2005, 4, 236-248.
55. Dayam, R.; Deng, J.; Neamati, N. HIV-1 integrase inhibitors: 2003-2004 update. Med. Res. Rev., 2006, 26, 271-309.
56. Savarino, A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin. Invest. Drugs, 2006, 15, 1507-1522.
57. Dayam, R.; Al-Mawsawi, L. Q.; Neamati, N. HIV-1 Integrase inhibitors: An emerging clinical reality. Drugs, 2007, 8, 155-168.
58. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 2000, 287, 646-650.
59. Markowitz, M.; Morales-Ramirez, J. O.; Nguyen, B. Y.; Kovacs, C. M.; Steigbigel, R. T.; Cooper, D. A.; Liporace, R.; Schwartz, R.; Isaacs, R.; Gilde, L. R.; Wenning, L.; Zhao, J.; Teppler, H. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquired Immune Defic. Syndr., 2006, 43, 509-515.
60. Grinsztejn, B.; Nguyen, B. Y.; Katlama, C.; Gatell, J. M.; Lazzarin, A.; Vittecoq, D.; Gonzalez, C. J.; Chen, J.; Harvey, C. M.; Isaacs, R. D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet, 2007, 369, 1261-1269.
61. Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem., 2006, 49, 1506-1508.
62. DeJesus, E.; Berger, D.; Markowitz, M.; Cohen, C.; Hawkins, T.; Ruane, P.; Elion, R.; Farthing, C.; Zhong, L.; Cheng, A. K.; McColl, D.; Kearney, B. P. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK- 303) in treatment-naive and treatment-experienced patients. J. Acquired Immune Defic. Syndr., 2006, 43, 1-5.
63. Zolopa, A. R.; Mullen, M.; Berger, D.; Ruane, P.; Hawkins, T.; Zhong, L.; Chuck, S.; Enejosa, J.; Kearney, B.; Cheng, A. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients; 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, February 25-28, 2007.
64. Jones, G.; Ledford, R.; Yu, F.; Miller, M.; Tsiang, M.; McColl, D. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303); 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, February 25-28, 2007; Los Angeles, CA, 2007.
65. Shimura, K.; Kodama, E.; Sakagami, Y., Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; Kano, M.; Ikeda, S.; Matsuoka, M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor Elvitegravir (JTK-303/GS-9137) J. Virol., 2008, 82, 764-774.
66. Sato, M.; Matsuda, T.; Okuda, S.; Kawakami, H.; Aramaki, H.; Shinkai, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Kiyonari, S.; Wamaki, S.; Takahashi, M.; Yamada, N.; Nagao, A. Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor. 2006, US 2006/0019906.
67. Cecchetti, V.; Parolin, C.; Moro, S.; Pecere, T.; Filipponi, E.; Calistri, A.; Tabarrini, O.; Gatto, B.; Palumbo, M.; Fravolini, A.; Palù, G. 6-Aminoquinolones as new potential anti-HIV agents. J. Med. Chem., 2000, 43, 3799-3802.
68. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C. M.; Nencioni, L.; Palamara, A. T.; Pommier, Y. Marchand, C. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, biological activities, and mechanism of action. J. Med. Chem., 2006, 49, 1939-1945.
69. Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W.; Tran, L. O.; Melamed, J. Y.; Langford, H. M.; Guare, J. P., Jr.; Zhuang, L.; Grey, V. E.; Vacca, J. P.; Holloway, M. K.; Naylor-Olsen, A. M.; Hazuda, D.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Schleif, W. A.; Gabryelski, L. J.; Young, S. D. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem., 2000, 43, 4923-4926.
70. Adams, M. M.; Bats, J. W.; Nikolaus, N. V.; Witvrouw, M.; Debyser, Z.; Engels, J. W. Microwave-assisted synthesis and anti-HIV integrase activity of novel fluoroquinolonenucleosides. Coll. Czech. Chem. Commun., 2006, 71, 978-990.
71. Debyser, Z.; Cherepanov, P.; Pluymers, W.; De Clercq, E. Assays for the evaluation of HIV-1 integrase inhibitors. Methods Mol. Biol., 2001, 160, 139-155.
72. Witvrouw, M.; Fikkert, V.; Vercammen, J.; Van Maele, B.; Engelborghs, Y.; Debyser, Z. Identification of authentic inhibitors of HIV-1 integration. Curr. Med. Chem., Anti-infective Agents, 2005, 4, 153-165.
73. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods, 1988, 20, 309-321.
74. Massa, S.; Corelli, F.; Mai, A.; Artico, M.; Panico, S.; Simonetti, N. Research on antibacterial and antifungal agents. XI. New antibacterial quinolones related to pirfloxacin. FARMACO, 1989, 44, 779-793.
75. Mugnaini, C.; Rajamaki, S.; Tintori, C.; Corelli, F.; Massa, S.; Witvrouw, M.; Debyser, Z.; Veljkovic, V.; Botta, M. Toward novel HIV-1 integrase binding inhibitors: Molecular modeling, synthesis, and biological studies. Bioorg. Med. Chem. Lett., 2007, 17, 5370-5373.
76. Pasquini, S.; Mugnaini, C.; Tintori, C.; Botta, M.; Trejos, A.; Arvela, R.; Larhed, M.; Witvrouw, M.; Michiels, M.; Christ, F.; Debyser, Z.; Corelli, F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 1. Synthesis and structure-Activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors J. Med. Chem., 2008, 51, 5125-5129.
77. Barreca, M. L.; De Luca, L.; Iraci, N.; Chimirri, A. Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase. J. Med. Chem., 2006, 49, 3994-3997.
78. Dayam, R.; Al-Mawsawi, L. Q.; Zawahir, Z.; Witvrouw, M.; Debyser, Z.; Neamati, N. Quinolone 3-carboxylic acid pharmacophore: Design of second generation HIV-1 integrase inhibitors. J. Med. Chem., 2008, 51, 1136-1144.
79. Wang, Z.; Vince, R. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. Bioorg. Med. Chem. Lett., 2008, 18, 1293-1296.
80. Di Marzo, V. Targeting the endocannabinoid system: To enhance or reduce? Nat. Rev. Drug Discov., 2008, 7, 438-455.
81. Tucci, S. A.; Halford, J. C. G.; Harrold, J. A.; Kirkham, T. C. Therapeutic potential of targeting the endocannabinoids; implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr. Med. Chem., 2006, 13, 2669-2680
82. Sorbera, L. A.; Castaner, J.; Silvestre, J. S. Rimonabant hydrochloride. Drugs Future, 2005, 30, 128-137.
83. Marketing authorization of European Medicines Agency (EMEA) valid throughout the European Union: 19 June 2006. European Public Assessment Report (EPAR). Acomplia. Protocol EMEA/H/C/666.
84. Malan, T. P., Jr.; Ibrahim, M. M.; Lai, J.; Vanderah, T. W.; Makriyannis, A.; Porreca, F. CB2 cannabinoid receptor agonists: Pain relief without psychoactive effects? Curr. Opin. Pharmacol., 2003, 3, 62-67.
85. Iwamura, H.; Suzuki, H.; Ueda, Y.; Kaya, T.; Inaba, T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther., 2001, 296, 420-425.
86. 2, regulates bone mass. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 696-701.
87. Sanchez, C.; de Ceballos, M. L.; del Pulgar, T. G.; Rueda, D.; Corbacho, C.; Velasco, G.; Galve-Roperh, I.; Huffman, J. W.; Ramon y Cajal, S.; Guzman, M. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res., 2001, 61, 5784-5789.
88. McKallip, R. J.; Lombard, C.; Fisher, M.; Martin, B. R.; Ryu, S.; Grant, S.; Nagarkatti, P. S.; Nagarkatti, M. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood, 2002, 100, 627-634.
89. Docagne, F.; Muneton, V.; Clemente, D.; Ali, C.; Loria, F.; Correa, F.; Hernangómez, M.; Mestre, L.; Vivien, D.; Guaza, C. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotection effects of cannabinoids through CB1 and CB2 receptor activation. Mol. Cell Neurosci., 2007, 34, 551-561.
90. Ramírez, B. G.; Blázquez, C.; Gómez del Pulgar, T.; Guzmán, M.; de Ceballos, M. L. Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J. Neurosci., 2005, 25, 1904-1913.
91. Manera, C.; Benetti, V.; Castelli, M. P.; Cavallini, T.; Lazzaretti, S.; Pibiri, F.; Saccomanni, G.; Tuccinardi, T.; Vannacci, A.; Martinelli, A.; Ferrarini, P. L. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4-(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J. Med. Chem., 2006, 49, 5947-5957.
92. Ferrarini, P. L.; Calderone, V.; Cavallini, T.; Manera, C.; Saccomanni, G.; Pani, L.; Ruiu, S.; Gessa, G. L. Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. Bioorg. Med. Chem., 2004, 12, 1921-1933.
93. Tuccinardi, T.; Ferrarini, P. L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. J. Med. Chem., 2006, 49, 984-994.
94. Manera, C.; Cascio, M. G.; Benetti, V.; Allara, M.; Tuccinardi, T.; Martinelli, A.; Saccomanni, G.; Vivoli, E.; Ghelardini, C.; Di Marzo, V.; Ferrarini, P. L. New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg. Med. Chem. Lett., 2007, 17, 6505-6510.
95. Stern, E.; Muccioli, G.; Millet, R.; Goossens, J. F.; Farce, A.; Chavatte, P.; Poupaert, J. H.; Lambert, D. M.; Depreux, P.; Hénichart, J. P. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: Synthesis, pharmacological properties and molecular modelling. J. Med. Chem., 2006, 49, 70-79.
96. Stern, E.; Muccioli, G.; Bosier, B.; Hamtiaux, L.; Millet, R.; Poupaert, J. H.; Hénichart, J. P.; Depreux, P.; Goossens, J. F.; Lambert, D. M. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: Consequences in receptor affinity and functionality. J. Med. Chem., 2007, 50, 5471-5484.
97. 2 cannabinoid receptor affinity and molecular modeling of substituted 1-phenyl-5-(1H-pyrrol-1-yl)-1 H-pyrazole-3-carboxamides, as potent pyrrole bioisosteres of rimonabant and SR144528. J. Med. Chem., 2008, 51, 1560-1576.
98. Pasquini, S.; Botta, L.; Semeraro, T.; Mugnaini, C.; Ligresti, A.; Palazzo, E.; Maione, S.; Di Marzo, V.; Corelli, F. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structureactivity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. J. Med. Chem., 2008, 51, 5075-5084.